NCT06390865 2025-11-04
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT06385496 2025-10-31
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01118689 2013-08-02
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Millennium Pharmaceuticals, Inc.
Phase 1 Completed